Low levels of IGF-1 have been found in preterm babies with impaired brain growth, ROP, and other morbidities; thus, a supplementation with recombinant human IGF-1 and its binding protein IGFBP-3 has been proposed as a potential strategy to reduce ROP occurrence and other preterm birth morbidities [133]. This evidence concerns the gene IGFBP3 and retinopathy of prematurity.